Cash Position: Ended the quarter with $509 million in cash. Cash Burn: $118 million during Q1 2025, including cash operating expenses and capital expenditures. Cash Runway: Expected to extend into mid-2027. Partnership Revenue: Over $450 million earned from collaborations to date. Operational Budget: Targeting less than or equal to $450 million for 2025, down from $600 million in 2024.

Warning! GuruFocus has detected 7 Warning Signs with RXRX.

Release Date: May 05, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has developed an advanced Recursion 2.0 platform, which integrates multimodal data and AI to enhance drug discovery and development efficiency. The company has successfully secured over $450 million through partnerships with major pharmaceutical companies like Sanofi and Roche Genentech, demonstrating strong external validation. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is focusing on a more streamlined and strategic R&D portfolio, prioritizing programs with higher probabilities of success. The company has unveiled a pipeline with more than five clinical and preclinical programs, including promising candidates like REC-617 and REC1245, which show potential in oncology and rare diseases. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is committed to disciplined capital allocation and has a cash runway extending into mid-2027, supported by strategic partnerships and efficient operational adjustments.

Negative Points

The company has decided to discontinue several programs, including NF2, CCM, and C. diff, due to strategic considerations and lack of differentiation in the current market landscape. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) faces challenges in the macroeconomic environment, necessitating disciplined and thoughtful decision-making to ensure long-term sustainability. The FAP program, while showing some preliminary efficacy, still requires further investigation and data to fully understand its potential and address non-responder issues. The company is strategically pausing the development of the LSD1 program to reassess opportunities for a more differentiated target product profile. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is navigating a competitive landscape in oncology and rare diseases, requiring continuous innovation and differentiation to maintain its market position.

Q & A Highlights

Q: Given your stated runway to mid-2027, what burn rate do you anticipate exiting '25 or entering '26 with? From where would you expect incremental efficiencies still to be derived? And do you plan to raise capital? A: We haven't given specific guidance on the runway, but if our budget for this year is $450 million or less, we're targeting a runway of less than that. We will continue to look for efficiencies across the organization, such as better contracts and integrating different parts of the business to lower costs. As for raising capital, we plan to continue our previous business practices, including using our ATM facility moderately.

Story Continues

Q: When can we see an option in on a molecule candidate from one of your four main partnerships? And any further insights on new levers in the OS for accelerating partnership programs to commercialization? A: We've already had 4 programs optioned in our collaboration with Sanofi and another with Roche Genentech. We believe these and other programs have the potential to move into our partners' pipelines, with significantly higher economics at later stages. For accelerating partnership programs, we're focusing on biology, chemistry, and development, using genomics, molecular dynamics, and clin tech capabilities to better understand patient populations and optimize drug design.

Q: Your pipeline prioritization leans heavily towards oncology. Do you generally see a pivot away from rare disease for your pipeline and platform? A: We believe both oncology and rare disease are fantastic areas for deploying our platform. Both areas often have genetic markers that provide an anchor point of biology. We'll continue to follow the data and drive both rare disease and oncology programs forward, without abandoning either in the near term.

Q: Talk about the FAP data shared at DDW and how is that differentiated from other programs that we may have seen in this space? A: The FAP data showed a median polyp burden reduction of 43% in efficacy evaluable patients, which is higher than the 20%-30% reductions seen with other programs like Celecoxib and rapamycin. We also observed changes in Spigelman scoring, indicating potential differentiation. However, this is early data, and we are continuing to investigate non-responders and other aspects as we gather more data.

Q: Do you expect any meaningful impact to your internal partnership strategy in light of the FDA's updated animal testing guidance? A: Recursion was built for an evolving regulatory framework, and we will continue to monitor updates from the FDA. Our discovery platform, predictive AME platform, and in vivo platform are generating large-scale data sets and building foundation models, positioning us to lead in this space and take advantage of regulatory updates.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments